Benzinga | Oct 1, 2020 08:05AM EDT

CymaBay Therapeutics To Present Data From Phase 2 Study Of Seladelpar In Patients With NASH At The Liver Meeting 2020 Nov. 13-16

NEWARK, Calif., Oct. 01, 2020 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases, today announced that data from a Phase 2 study of seladelpar in nonalcoholic steatohepatitis (NASH) will be delivered during The Liver Meeting Digital Experience(tm) 2020 (TLMdX) of the American Association for the Study of Liver Diseases (AASLD) which will be held online November 13th -- 16th.